openregs: documents: 7 rows where docket_id = "FDA-2017-P-7033" sorted by posted

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

comment_end_date: A FULL UTC INSTANT, not a calendar date, despite the column name: '2026-08-29T03:59:59Z' is 11:59:59 PM EASTERN on 2026-08-28. Federal comment periods close at 11:59:59 PM Eastern, so the UTC calendar date is ONE DAY LATER than the official deadline on every end-of-day close — 444,689 of the 444,690 populated rows (measured 2026-09-06). Convert to America/New_York before presenting a deadline, and compare with julianday(comment_end_date) > julianday('now'): a plain > datetime('now') is a TEXT comparison between two different formats and keeps already-closed dockets matching for up to ~20 hours. The sibling column on open_comments.documents WAS corrected to an Eastern calendar date (queue #498); this one is unchanged and still an instant — the two databases do not agree on grain. (queue #644)
comment_start_date: A FULL UTC INSTANT, not a calendar date, despite the column name — same grain as comment_end_date on this table. Convert to America/New_York before presenting it. (queue #644)

7 rows where docket_id = "FDA-2017-P-7033" sorted by posted_date descending

descending

id	agency_id	docket_id	title	document_type	subtype	posted_date ▲	posted_year	posted_month	comment_start_date	comment_end_date	last_modified	object_id
FDA-2017-P-7033-0007	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Response Letter from FDA CDER to Jubilant Generics Limited	Other	Approval	2023-04-19T04:00:00Z	2023	4	2023-04-19T04:00:00Z		2023-04-19T20:15:12Z	090000648595eec0
FDA-2017-P-7033-0004	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Exhibit 2 RLD Label re Citizen Petition from Jubliant Generics Limited	Supporting & Related Material	Background Material	2017-12-29T05:00:00Z	2017	12			2018-01-02T16:51:33Z	0900006482d84da8
FDA-2017-P-7033-0006	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Exhibit 4 Oxetol Dosage & Drug Information re Citizen Petition from Jubliant Generics Limited	Supporting & Related Material	Background Material	2017-12-29T05:00:00Z	2017	12			2018-01-02T16:51:56Z	0900006482d84daa
FDA-2017-P-7033-0001	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Citizen Petition from Jubliant Generics Limited	Other	Citizen Petition	2017-12-29T05:00:00Z	2017	12	2017-12-29T05:00:00Z	2018-06-28T03:59:59Z	2018-01-02T16:50:17Z	0900006482d84d79
FDA-2017-P-7033-0002	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Acknowledgment Letter from FDA DDM to Jubilant Generics Limited	Other	Acknowledgement Letter/Receipt	2017-12-29T05:00:00Z	2017	12	2017-12-29T05:00:00Z		2018-01-02T16:50:45Z	0900006482d84da4
FDA-2017-P-7033-0003	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Exhibit 1 Orange Book Listing re Citizen Petition from Jubliant Generics Limited	Supporting & Related Material	Background Material	2017-12-29T05:00:00Z	2017	12			2018-01-02T16:51:21Z	0900006482d84da7
FDA-2017-P-7033-0005	FDA	Requests that the FDA determine that the drug product, Oxcarbazepine Oral Tablet 450 mg (dual scored) is suitable for consideration in an Abbreviated New Drug Application FDA-2017-P-7033	Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubliant Generics Limited	Supporting & Related Material	Background Material	2017-12-29T05:00:00Z	2017	12			2018-01-02T16:51:45Z	0900006482d84da9

Advanced export

JSON shape: default, array, newline-delimited, object

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;